









Markets
/
Stocks
/
nasdaq-lixt
/

Lixte Biotechnology Holdings Inc

LIXT

2.950USD

-0.070-2.32%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

16.83MMarket Cap

LossP/E TTM



Lixte Biotechnology Holdings Inc

2.950

-0.070-2.32%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lixte Biotechnology Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Lixte Biotechnology Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 216 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lixte Biotechnology Holdings Inc's Score

Industry at a Glance

Industry Ranking

216 / 392

Overall Ranking

445 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lixte Biotechnology Holdings Inc Highlights

StrengthsRisks

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. The LB-100 series has activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Undervalued

The company’s latest PE is -2.46, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 569.27K shares, increasing 15.08% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 74.94K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Lixte Biotechnology Holdings Inc is 7.00, ranking 169 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lixte Biotechnology Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Lixte Biotechnology Holdings Inc is 5.91, ranking 356 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.46, which is -80.64% below the recent high of -0.48 and -92.60% above the recent low of -4.74.

Score

Industry at a Glance

Previous score

5.91

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 216/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Lixte Biotechnology Holdings Inc. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Lixte Biotechnology Holdings Inc is 6.10, ranking 281 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.69 and the support level at 2.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.18

Change

-0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Sell

RSI(14)

35.357

Neutral

STOCH(KDJ)(9,3,3)

15.899

Sell

ATR(14)

0.383

Low Volatility

CCI(14)

-133.437

Sell

Williams %R

90.598

Oversold

TRIX(12,20)

-0.495

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.226

Sell

MA10

3.430

Sell

MA20

3.394

Sell

MA50

3.788

Sell

MA100

4.221

Sell

MA200

3.450

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Lixte Biotechnology Holdings Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 9.98%, representing a quarter-over-quarter increase of 71.38%. The largest institutional shareholder is The Vanguard, holding a total of 74.94K shares, representing 1.31% of shares outstanding, with 576.87% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Orca Capital GmbH

120.01K

The Vanguard Group, Inc.

Star Investors

48.53K

+802.27%

Renaissance Technologies LLC

Star Investors

73.15K

Desjardins Securities Inc.

50.85K

DRW Securities, LLC

48.48K

Intracoastal Capital, L.L.C.

42.00K

Geode Capital Management, L.L.C.

41.44K

+100.16%

Ethos Financial Group, LLC

24.81K

State Street Investment Management (US)

17.40K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lixte Biotechnology Holdings Inc is 2.75, ranking 203 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.